Eleos Health
Series C in 2025
Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.
Lighthouse
Series C in 2024
Lighthouse is a commercial platform tailored for the travel and hospitality industry, specializing in hotel management solutions. The company offers a cloud-based platform that visualizes and leverages data to enhance business success. By providing actionable market insights and business intelligence tools, Lighthouse enables hoteliers and hotel management companies to make informed revenue and distribution decisions. Its services include real-time data analytics, which empower users to maximize property occupancy rates and increase revenue and profit. Formerly known as OTA Insight, Lighthouse aims to transform complex market dynamics into manageable strategies that foster growth in the hospitality sector.
Founded in 2014 by Stanford University Biodesign Fellows collaborating with leading urologists, Zenflow develops a novel spring device to alleviate permanent benign prostatic hyperplasia (BPH) symptoms in men. Its minimally invasive solution preserves natural anatomy and improves patient experience.
Canoe Software Inc. provides a sophisticated software solution focused on financial document and data management. Founded in 2013 and based in New York, the company specializes in automating the extraction and organization of investment documents using artificial intelligence and machine learning technologies. This enables users to efficiently convert unstructured data from various formats, such as PDFs, into actionable insights, thereby improving operational efficiency. Canoe's platform supports a wide range of clients, including single and multi-family offices, endowments, foundations, pensions, investment consultants, and financial institutions, facilitating better management of post-investment operations, monitoring, and reporting. By streamlining the data management process, Canoe helps minimize manual data entry and enhances the accuracy of financial reporting and analysis.
Odaseva is a company specializing in data management solutions for large enterprises utilizing Salesforce. It offers a comprehensive cloud-based platform that focuses on data protection, privacy, and governance. The Odaseva Enterprise Data Security Platform is designed to ensure the confidentiality, integrity, and availability of critical business information by providing integrated security products and services. Key features of the platform include backup and recovery, archiving, monitoring of governor limits, and compliance support for regulations such as GDPR. By enabling businesses to take full control of their data, Odaseva helps eliminate risks and facilitates confident digital transformation.
Canary Technologies
Series C in 2024
Canary Technologies is a hospitality technology company that modernizes hotel operations. It offers a guest management platform featuring contactless check-in, digital authorizations, and an amenity store. The platform drives revenue growth, improves staff productivity, ensures compliance, and reduces fraud.
Ashby is a developer of recruitment software tailored for high-growth companies. The company creates enterprise-grade employment solutions designed to enhance the hiring processes of organizations. Its platform enables company leaders, recruiters, and hiring managers to streamline their recruitment efforts, thereby improving overall efficiency and productivity. Ashby's software is accessible for teams of various sizes, allowing them to effectively meet their hiring objectives while fostering organizational growth.
Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.
1upHealth
Series C in 2023
Founded in 2017, 1upHealth operates a health data aggregation platform that securely centralizes patient records from various electronic medical systems. Its platform enables patients to control and share their consolidated digital health record with providers, while also allowing developers to access clinical data from connected clinics and hospitals.
ABK Biomedical
Series C in 2022
Founded in 2012, ABK Biomedical specializes in developing embolotherapeutic products for treating hypervascular tumors. Its primary focus is improving treatment options for patients through innovative microsphere technology.
Pulmocide
Series C in 2022
Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.
Proximie is a health technology company that enables surgeons worldwide to collaborate remotely using augmented reality, artificial intelligence, and machine learning. Its platform allows surgeons to visually guide complex surgeries, democratizing access to advanced surgical knowledge.
RightHand Robotics
Series C in 2022
RightHand Robotics, Inc. is a manufacturer of robotic order-picking systems that streamline supply chain logistics for various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company specializes in robotic solutions that automatically grasp a wide variety of items from bins and cases. Its flagship products include the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor designed to enhance the robots' ability to handle items gently and correct errors. RightHand Robotics focuses on providing end-to-end solutions that simplify integration and adaptation to diverse customer workflows, ultimately reducing the costs associated with order fulfillment across sectors such as electronics, apparel, grocery, and pharmaceuticals.
Stride Health
Series C in 2021
Stride Health, Inc. is a health benefits platform that specializes in providing affordable health coverage options for independent workers and part-time employees in the United States. The company offers a range of services, including dental plans, doctor and prescription insurance plans, and various health coverage options tailored to meet the needs of its customers. Stride Health simplifies the enrollment process by guiding users through selecting the most cost-effective health plans, aiming to optimize their tax benefits and enhance their take-home pay. Founded in 2013 and based in San Francisco, California, the company was previously known as Covered, Inc. and rebranded to Stride Health, Inc. in March 2013. Stride Health also provides personal advisory services to assist clients in navigating the complexities of their health insurance options.
Founded in 2014 by Fredrik Skantze and Per Made, Funnel is a software company specializing in marketing analytics. It integrates with over 400 data sources to automate data collection from various advertising platforms, catering to e-commerce companies, media agencies, brands, B2B businesses, mobile apps, and gaming companies.
Founded in 2013, Oviva specializes in digital behavior change programs for managing type 2 diabetes and obesity. Their platform combines smartphone apps and learning portals, supported by dietitian-led coaching, enabling patients to improve their health remotely and reducing healthcare system costs.
Carrot Fertility
Series C in 2021
Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.
MoEngage, Inc. is a technology company that provides a cloud-based user analytics and engagement platform aimed at enhancing customer retention and lifetime value for consumer businesses. Founded in 2014 and headquartered in San Francisco, California, the company serves various industries, including e-commerce, telecommunications, travel and hospitality, and banking and finance. MoEngage's platform enables businesses to deliver personalized interactions through multiple channels, such as push notifications, in-app messaging, web push, and SMS, all managed from a single dashboard. With a focus on machine learning, the platform optimizes customer engagement by analyzing user behavior and delivering tailored recommendations. MoEngage also has offices in several international locations, including Bengaluru, Singapore, London, Jakarta, Bangkok, Ho Chi Minh City, and Berlin.
SonderMind
Series C in 2021
SonderMind is a Denver-based digital health company established in 2017, specializing in accessible and approachable mental health services. It operates an online platform that connects individuals with a network of licensed therapists, offering a range of services including video telehealth and in-person sessions. SonderMind focuses on various mental health conditions such as anxiety, depression, ADHD, and PTSD, among others. The company aims to streamline the process of finding and accessing mental health care, ensuring a good match between clients and therapists, while also supporting therapists by handling administrative and billing tasks.
Orient Speech Therapy
Series C in 2021
Orient Speech Therapy Center specializes in providing professional speech and language therapy services for children facing communication challenges, including those with autism or speech disorders. The center focuses on the early screening, clinical diagnosis, and therapeutic interventions essential for improving children's speech and social skills. It offers a range of refined curricula designed specifically for young learners, including the Star Curriculum, phonics and oral muscle courses, expression courses, and exercise classes. Through these structured programs, Orient Speech Therapy Center aims to enhance the communicative abilities of children, enabling them to express themselves more effectively and engage socially.
Pulmocide
Series C in 2021
Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.
CareStack
Series C in 2021
CareStack is a company that provides an all-in-one cloud-based platform designed to streamline dental practice management. The platform integrates various functionalities including patient engagement, scheduling, telehealth conferencing, charting, automated reminders, claims and billing, and business insights. This comprehensive solution aims to enhance operational efficiency, improve patient care, and increase financial success for dental practices. CareStack's mission is to support dentists in achieving better practice management and an improved quality of life through its technology-driven offerings.
SnapDocs, Inc. is a real estate technology company that specializes in digital mortgage closings. Founded in 2013 and headquartered in San Francisco, California, SnapDocs provides a platform that connects lenders, title companies, notary signing agents, and homebuyers, facilitating a streamlined closing process. The platform automates interactions among these participants, ensuring efficiency, accuracy, and consumer satisfaction. It offers features such as performance metrics for mobile notary signing agents, customizable workflows for lenders and real estate professionals, and early access to closing packages for homebuyers. By leveraging advanced automation and patented technology, SnapDocs enhances the closing experience, enabling clients to save time and reduce costs while maintaining compliance. The company's focus on improving both borrower experience and business outcomes positions it as a leading solution in the mortgage closing industry.
Checkmate Pharmaceuticals
Series C in 2020
Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.
PatientPing
Series C in 2020
PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.
Devoted Health
Series C in 2020
Founded in 2017, Devoted Health is dedicated to enhancing the health and well-being of older Americans by offering integrated Medicare Advantage plans. They provide personalized care through a combination of local providers, virtual and in-home care, dedicated guides, and advanced technology.
Whatfix provides a digital adoption platform that enhances user productivity, ensures process compliance, and improves user experience across various applications. It offers simulated application environments for training and no-code application analytics.
MoEngage, Inc. is a technology company that provides a cloud-based user analytics and engagement platform aimed at enhancing customer retention and lifetime value for consumer businesses. Founded in 2014 and headquartered in San Francisco, California, the company serves various industries, including e-commerce, telecommunications, travel and hospitality, and banking and finance. MoEngage's platform enables businesses to deliver personalized interactions through multiple channels, such as push notifications, in-app messaging, web push, and SMS, all managed from a single dashboard. With a focus on machine learning, the platform optimizes customer engagement by analyzing user behavior and delivering tailored recommendations. MoEngage also has offices in several international locations, including Bengaluru, Singapore, London, Jakarta, Bangkok, Ho Chi Minh City, and Berlin.
WelbeHealth
Series C in 2020
WelbeHealth serves frail seniors through its PACE (Program of All-Inclusive Care for the Elderly) model, providing comprehensive medical and social care. This enables participants to live better, longer, and more independently. The company coordinates various aspects of care, including medical appointments, therapy sessions, transportation, meals, and personal care services.
Wellframe
Series C in 2019
Wellframe Inc. is a Boston-based company that specializes in digital care management and health advocacy solutions. Founded in 2011, it partners with health plans across the country to enhance the relationship between healthcare providers and members. Wellframe's offerings include a mobile application that facilitates daily health reporting, a care team dashboard to prioritize patient needs, and an array of communication tools for two-way messaging. The company also provides comprehensive operational services, such as implementation support, recruiting, and analytics. Additionally, Wellframe's platform employs real-time data and artificial intelligence to deliver personalized care protocols, enabling caregivers to monitor patient status effectively and identify when intervention is necessary. By focusing on mobile patient engagement and care management, Wellframe aims to improve health outcomes and empower individuals in managing their health.
Recurly, Inc. is a provider of enterprise-class subscription management and billing solutions aimed at optimizing revenue growth for businesses across various industries, including digital media, streaming, publishing, SaaS, consumer goods, and professional services. Founded in 2009 and headquartered in San Francisco, California, with additional offices in Boulder, Colorado, and New Orleans, Louisiana, Recurly simplifies the complexities of subscription billing and revenue optimization. Its platform facilitates recurring billing automation, offering features such as customizable hosted billing pages, account management services, and actionable insights to enhance decision-making. By reducing subscriber churn and improving operational efficiency, Recurly enables businesses to quickly integrate payment solutions and focus on growth. The company is also a Level 1 PCI compliant service provider, which minimizes costs associated with PCI compliance for its clients.
Protenus, Inc. is a healthcare compliance analytics company based in Baltimore, Maryland, which was founded in 2014. The company specializes in an AI-driven platform designed to audit access to patient records across health systems in the United States. Protenus' technology identifies risks such as inappropriate access to patient data and the misuse of controlled substances by healthcare staff. By automating the detection of policy violations and other anomalous behaviors, the platform supports healthcare organizations in protecting patient privacy and reducing operational risks. Protenus is recognized for its innovation and commitment to fostering safe patient outcomes while enhancing the reputation of healthcare providers. The company has received accolades such as being named one of America's Best Startup Employers by Forbes and recognized as a Great Place to Work.
Simon Data
Series C in 2019
Simon Data develops a customer data platform designed to enhance campaign performance via precise segmentation and personalization. Its platform identifies purchase intent, predicts churn, estimates customer lifetime value, and enables brands to deliver personalized experiences across channels.
Artemis Health
Series C in 2019
Artemis Health Inc. is a health data analytics company that specializes in providing self-insured employers with a comprehensive platform designed to optimize employee benefit programs. Founded in 2013 and headquartered in Salt Lake City, Utah, the company offers actionable insights into benefit programs, highlighting opportunities and gaps that enable employers to make informed decisions. Its platform allows users to identify issues within their benefits offerings, share insights with relevant stakeholders, and track the effectiveness of implemented solutions. By facilitating data-driven decision-making, Artemis Health helps employers enhance their programs while effectively managing healthcare expenditures and improving overall employee health and wellness coverage.
Checkmate Pharmaceuticals
Series C in 2018
Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.
PharmEasy
Series C in 2018
PharmEasy is a health tech startup founded in 2015 by Dharmil Sheth, Mikhil Innani, and Dhaval Shah as a subsidiary of Ascent Health. The company operates an online platform that offers a range of healthcare services, including teleconsultation, medicine deliveries, and diagnostic test sample collections. By digitizing the pharmaceutical supply chain, PharmEasy connects patients with local pharmacies and diagnostic centers, facilitating access to essential medicines and healthcare products. This approach aims to make healthcare services more available, affordable, and accessible to patients.
Quartet Health
Series C in 2018
Founded in 2014, Quartet Health operates a cloud-based platform facilitating communication between medical providers and behavioral health specialists for improved patient care. The platform works with health plans and systems to provide actionable insights on behavioral health conditions, enhancing patient outcomes.
Threat Stack
Series C in 2017
Threat Stack is a provider of cloud security solutions that assist DevOps and SecOps teams in securely leveraging cloud environments while addressing complex security challenges. Its flagship offering, the Threat Stack Cloud Security Platform, delivers comprehensive security monitoring and risk assessment, enabling organizations to detect insider threats, external attacks, and compliance gaps in real-time. The platform offers full-stack security observability across various infrastructures, including cloud, hybrid-cloud, and containerized systems, and spans the entire application development lifecycle. By facilitating proactive risk management and supporting regulatory compliance, Threat Stack empowers enterprises to enhance their overall security posture and effectively manage risks associated with their digital operations.
VYNE Therapeutics
Series C in 2017
VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.
Promentis Pharmaceuticals
Series C in 2017
Founded in 2006, Promentis Pharmaceuticals is a biopharmaceutical company based in Milwaukee, Wisconsin. It develops therapies targeting the central nervous system for treating neuropsychiatric disorders such as impulse control disorders and obsessive-compulsive disorder.
Snapsheet
Series C in 2016
Snapsheet is a leading provider of cloud-based claims management software. It enhances customer experience through tech-enabled appraisal services, focusing on engagement and intelligent automation. The company's Snapsheet Cloud suite improves organizational agility and delivers transformational benefits to over 100 clients, including major insurance carriers and disruptors.
TraceLink
Series C in 2016
TraceLink develops and provides track-and-trace solutions for the life sciences supply chain. Its primary offering is TraceLink Life Sciences Cloud, enabling pharmaceutical serialization and compliance with regulations like EU Falsified Medicines Directive. The company serves pharmaceutical companies, distributors, and repackagers, with strategic partnerships to enhance its services.
Hua Medicine
Series C in 2016
Hua Medicine is a clinical-stage drug development company in China focused on therapies for diabetes and CNS disorders. It develops Dorzagliatin (also known as HMS5552), an oral, first-in-class glucokinase activator for type 2 diabetes, and has advanced Dorzagliatin into NDA-enabling work and Phase III trials in China, including studies in drug-naive and metformin-treated patients. The company is pursuing Dorzagliatin in combination with metformin and in combination with DPP-4 inhibitors, SGLT-2 inhibitors, and insulin in various development stages. In addition, Hua Medicine is developing mGluR5 candidates for Parkinson's disease and related levodopa-induced dyskinesia. The company was founded in 2011 and is headquartered in Shanghai, China.
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.
Aclaris Therapeutics
Series C in 2015
Aclaris Therapeutics is a United States-based clinical-stage biopharmaceutical company focused on developing novel therapies for immuno-inflammatory diseases and dermatology, aiming to address unmet medical and aesthetic needs where treatment options are limited. The company operates two segments, therapeutics and contract research, with the therapeutics business pursuing innovative treatments for immuno-inflammatory conditions while the contract research segment provides laboratory services. Its pipeline includes Zunsemetinib, an oral MK2 inhibitor, and ATI-2138, among other drug candidates.
Iora Health
Series C in 2015
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.
Innovent Biologics
Series C in 2015
Innovent Biologics is a China-based biopharmaceutical company that discovers, develops, manufactures, and commercializes monoclonal antibodies. It operates a platform for antibody therapeutics across oncology, ophthalmology, immunology, and metabolic diseases, with Tyvyt (sintilimab) as its core asset, a PD-1 inhibitor used in first-line and other cancer indications. The company develops a broad pipeline including biosimilars and novel antibodies and provides distribution, consulting, and R&D services. It maintains strategic collaborations with global partners, including a co-development arrangement with MD Anderson Cancer Center and an alliance with Eli Lilly for TYVYT, and has more than 30 collaborations with major pharmaceutical companies. Innovent is listed on the Hong Kong Exchange and maintains manufacturing and development capabilities in China with a growing portfolio of oncology and non-oncology products marketed domestically and internationally.
REGENXBIO
Series C in 2015
REGENXBIO is a clinical-stage biotechnology company developing gene therapy product candidates using its proprietary NAV Technology Platform. This platform delivers genes to cells to address genetic defects or produce therapeutic proteins. REGENXBIO's pipeline includes RGX-314 for wet age-related macular degeneration, RGX-121 and RGX-111 for mucopolysaccharidoses, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II disease, and RGX-501 for homozygous familial hypercholesterolemia. The company also licenses its platform to other biopharmaceutical companies.
Flywire facilitates global payments for educational institutions and their students worldwide. It offers a secure platform supporting diverse payment methods in over 140 currencies across 240 countries.
ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.
Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations.
Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.
NextWave Pharmaceuticals
Series C in 2011
NextWave Pharmaceuticals is a Cupertino, California-based pharmaceutical company that specializes in the development and commercialization of innovative products utilizing proprietary drug delivery technology. The company is primarily focused on creating once-daily liquid medications aimed at treating attention deficit/hyperactivity disorder (ADHD). By leveraging its unique drug delivery systems, NextWave Pharmaceuticals enables healthcare providers to effectively address various disorders related to the central nervous system, enhancing treatment options for patients.
ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.
Tetraphase Pharmaceuticals
Series C in 2010
Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.
Ironwood Pharmaceuticals
Series C in 2002
Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.